COVID-19 Continues To Drive Demand For Baxter’s Acute Therapies Portfolio
Demand for Baxter's acute therapy products helped offset declines across its advanced surgery, pharmaceuticals and medication-delivery businesses in the second quarter.
You may also be interested in...
The pandemic may accelerate a move toward versatile, single-solution renal replacement therapy in intensive care.
The COVID-19 pandemic has increased demand for products from all of Baxter’s businesses except its advanced surgery division. Overall, the diversified company’s global sales were up 8% in the first quarter.
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.